0001415889-23-016908.txt : 20231222 0001415889-23-016908.hdr.sgml : 20231222 20231222180013 ACCESSION NUMBER: 0001415889-23-016908 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231220 FILED AS OF DATE: 20231222 DATE AS OF CHANGE: 20231222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gillies Hunter CENTRAL INDEX KEY: 0001868997 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 231511017 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-12222023_061202.xml X0508 4 2023-12-20 0001798749 Aerovate Therapeutics, Inc. AVTE 0001868997 Gillies Hunter C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false CHIEF MEDICAL OFFICER 1 Common Stock 2023-12-13 4 M 0 4000 1.74 A 7251 D Common Stock 2023-12-20 4 S 0 4000 19.50 D 3251 D Stock Option (Right to Buy) 1.74 2023-12-20 4 M 0 2924 0 D 2030-09-03 Common Stock 2924 9023 D Stock Option (Right to Buy) 1.74 2023-12-20 4 M 0 1076 0 D 2030-09-03 Common Stock 1076 10027 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. /s/ George A. Eldridge, Attorney-in-Fact 2023-12-22